At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
Recombinant Human Plasma Gelsolin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma Gelsolin Added to Standard of Care in Subjects Hospitalized for Acute Community-acquired Pneumonia
In Brief
A Phase 2 clinical trial evaluating Recombinant Human Plasma Gelsolin and Normal Saline Placebo for Community-acquired Pneumonia. Completed, enrolled 33 participants across 8 sites in 2 countries.
Detailed Summary
A Phase 1b/2a, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma gelsolin (rhu-pGSN) Added to Standard of Care in Subjects Hospitalized for Acute Community-acquired Pneumonia (CAP)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommunity-acquired Pneumonia
CountriesAustralia, Georgia
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartAug 2018
Primary CompletionApr 2019
TodayJul 2026
First PostedMar 15, 2018
Enrollment StartAug 28, 2018
Primary CompletionApr 2, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.3 years ago
Interventions
Recombinant Human Plasma Gelsolindrug
Recombinant human plasma gelsolin lyophilized for reconstitution, reconstituted in sterile water
Normal Saline Placeboother
Normal saline in volume equivalent to drug